Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study
Giustino G, Kirtane AJ, Baber U, Généreux P, Witzenbichler B, Neumann FJ, Weisz G, Maehara A, Rinaldi MJ, Metzger C, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Brodie BR, Stuckey TD, Gurbel PA, Dangas GD, Francese DP, Ozan O, Mehran R, Stone GW. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. The American Journal Of Cardiology 2016, 117: 1877-1883. PMID: 27131611, DOI: 10.1016/j.amjcard.2016.03.034.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnemiaAspirinBlood PlateletsClopidogrelCoronary Artery DiseaseDrug Therapy, CombinationDrug-Eluting StentsEuropeFemaleHemorrhageHumansIncidenceMaleMiddle AgedMyocardial IschemiaPercutaneous Coronary InterventionPlatelet AggregationPlatelet Aggregation InhibitorsProspective StudiesRegistriesRisk AssessmentRisk FactorsSurvival RateTiclopidineUnited StatesConceptsHigh platelet reactivityDrug-Eluting Stents studyMajor adverse cardiac eventsAdverse cardiac eventsDual antiplatelet therapyPlatelet reactivityAntiplatelet therapyMajor bleedingCause mortalityCardiac eventsMultivariate adjustmentStent studiesWorld Health Organization criteriaImpact of anemiaPresence of anemiaPercutaneous coronary interventionDrug-eluting stentsIschemic riskBleeding riskClinical confoundersCoronary interventionAnemic patientsClinical outcomesHemoglobin levelsStudy cohortRelation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study
Giustino G, Kirtane AJ, Généreux P, Baber U, Witzenbichler B, Neumann FJ, Weisz G, Maehara A, Rinaldi MJ, Metzger C, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Brodie BR, Stuckey TD, Dangas GD, Francese DP, Litherland C, Mehran R, Stone GW. Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. The American Journal Of Cardiology 2016, 117: 1703-1713. PMID: 27067621, DOI: 10.1016/j.amjcard.2016.03.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood PlateletsCause of DeathCoronary ThrombosisDose-Response Relationship, DrugDrug Therapy, CombinationDrug-Eluting StentsFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPlatelet CountPostoperative HemorrhageProspective StudiesRisk FactorsSurvival RateTreatment OutcomeUnited StatesConceptsDrug-Eluting Stents studyDual antiplatelet therapyPlatelet countHigher platelet countsDrug-eluting stentsPlatelet reactivityAntiplatelet therapyMultivariable adjustmentThrombotic complicationsStent studiesHigh riskCoronary artery implantationResidual platelet reactivitySimple hematological parametersSpontaneous myocardial infarctionLow platelet countBleeding riskCause mortalityDES implantationCrude riskPlatelet inhibitionHemorrhagic riskRisk stratificationStudy cohortThrombotic events